1996/06/01 by Henry David Abraham, Anitra Mamen · 6 citations
Psychology · Medicine · Neuroscience · #Psychedelics and Drug Studies #Schizophrenia research and treatment #Sleep and Wakefulness Research
paper · doi:10.1097/00004714-199606000-00008
openalex publication_date 1996/06/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/26
Risperidone, a novel antipsychotic agent, is an antagonist of postsynaptic serotonin-2 and dopamine D2 receptors. In certain individuals, the hallucinogenic drug lysergic acid diethylamide (LSD) is associated with apparently lifelong continuous visual disturbances, characterized in DSM-IV as hallucinogen-persisting perception disorder (HPPD). Because the hallucinogenic mechanism of LSD is known to act in part at postsynaptic serotonin-2 receptors, it is noteworthy that three HPPD patients treated with risperidone reported an exacerbation of LSD-like panic and visual symptoms. We conclude that HPPD may be a relative contraindication for the use of risperidone.